News and Trends 23 Nov 2022 UCB publishes Lennox-Gastaut syndrome study data UCB has announced the publication of long-term open-label extension (OLE) study results of FINTEPLA (fenfluramine) CIV in the journal Epilepsia. Long-term efficacy and safety findings showed that FINTEPLA, when added to a patient’s current anti-epileptic treatment regimen for seizures associated with Lennox-Gastaut syndrome (LGS), was effective in reducing the frequency of multiple seizure types and […] November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 15 Nov 2022 Sequana Medical has positive results for heart failure therapy drug Sequana Medical has had some very positive top-line results from a phase 2a study, that the company says reinforces its view that direct sodium removal (DSR) is a potential disease modifying heart failure therapy. The study called SAHARA was testing its first-generation DSR product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients with […] November 15, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 14 Nov 2022 BioSenic’s autoimmune disease platform adapting to meet unmet medical needs BioSenic’s systemic autoimmune disease platform, originally designed by Medsenic, is now developing controlled dosages and new formulations adapted to a significant number of important indications with unmet medical needs. BioSenic specializes in serious autoimmune and inflammatory diseases as well as cell repair. The update follows the announcement of the merger between Bone Therapeutics and Medsenic […] November 14, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 Novadip Biosciences raises €40M for bone defect treatments Novadip Biosciences has raised an additional €40 million ($39.2 million) in a series B equity round and non-dilutive funding. The clinical-stage biopharma company is developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. The funding will accelerate the clinical development of two of […] November 4, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2022Beyond Biotech podcast 20: BioWin, eTherapeutics, CMT Research Foundation This week, we have three interviews, and four guests. We chatted with Keith Fargo, chief scientific officer at the CMT Research Foundation; François Colery, head of the Talent Now initiative and Sylvie Ponchaut, managing director, from BioWin; and e-therapeutics’ CEO, Ali Mortazavi. We also have our weekly contribution from global commercial real estate services company […] October 28, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Domain Therapeutics to start clinical trials of solid tumor treatment Domain Therapeutics says its immuno-oncology candidate has been cleared in Belgium and France, leading to a phase I clinical trial. It has cleared its clinical trial applications with the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) […] October 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 Biocartis starts European commercialization of liver cancer test Biocartis Group NV has started the commercialization in Europe of the HepatoPredict test as a CE-IVD marked manual kit. The test, developed by Portuguese biotech company Ophiomics, is a prognostic diagnostic test that supports the decision of liver transplantation in patients with hepatocellular carcinoma (HCC). Herman Verrelst, chief executive officer of Biocartis, said: “We are […] October 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Oct 2022 Ziphius and UZ Ghent collaborating on manufacture of saRNA-based vaccines Ziphius Vaccines, a biopharmaceutical company developing vaccines and therapeutics based on self-amplifying RNA (saRNA), and UZ Ghent have entered a public-private collaboration for the scale up and manufacturing of prophylactic self-amplifying RNA vaccines based on GMP (good manufacturing practice) standards. The collaboration is a first in Europe where a university hospital produces GMP grade prophylactic […] October 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Study data for glioblastoma treatment confirms safety and tolerability profile The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme (GBM) have been reported by Australian-based Telix Pharmaceuticals Ltd. The therapy, TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) administered with external beam radiation therapy (EBRT) and the primary objective was to evaluate and test the safety and tolerability profile of the intravenous therapy […] September 22, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 PDC*line Pharma presents results from phase I/II trial PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, has revealed the first results of its PDC-LUNG-101 phase I/II clinical trial with PDC*lung01. PDC*lung01 is the company’s therapeutic off-the shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). The preliminary data was presented at […] September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 7 Sep 2022 The biggest private biotech investments in August 2022 The healthcare-focused companies Orna Therapeutics, F2G and Sironax bagged the biggest biotech investments in August 2022, with mRNA vaccines, genomics and fermentation technology attracting big funding rounds. As many took a well-deserved vacation in the month of August 2022, the world of biotech remained busy with fundraising. Sit back and browse our lists of the […] September 7, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 KU Leuven spin-off AstriVax raises €30M for vaccine platform – first stop, yellow fever A Belgian university spinoff has generated the biggest seed capital financing in the institution’s history. Closing with €30 million ($30 million), AstriVax will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various […] August 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email